How it works, simply
It replaces growth-hormone signaling and affects downstream growth factors such as IGF-1.
What the evidence tells us
Treatment of hormone deficiency does not establish benefits or safety for healthy-person anti-aging use.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Glucose intolerance, fluid retention and intracranial hypertension are relevant concerns.
- Contraindications include certain acute critical illnesses and active malignancy.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates growth-hormone receptors and downstream IGF-1 signaling in diagnosis-specific populations.
Sponsor or developer: Multiple manufacturers
Studied or labeled topics: Growth-hormone deficiency, Selected growth disorders, Selected catabolic conditions
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: GENOTROPIN prescribing information ↗ · Regulator · Aug 06, 2026
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.